| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9267223 | Joint Bone Spine | 2005 | 4 Pages |
Abstract
Conclusion.- The infliximab continuation rate in everyday practice in patients with RA (67% after 2Â years) was consistent with published data and with the results of controlled trials.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Daniel Wendling, Guewen-Edouard Materne, Fabrice Michel, Anne Lohse, Gaelle Lehuede, Eric Toussirot, Jacques Massol, Marie-Christine Woronoff-Lemsi,